Literature DB >> 28049571

Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.

Charles L Bennett1, Oliver A Sartor2, James O Armitage3, Hagop Kantarjian4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28049571     DOI： 10.1016/S1470-2045(16)30653-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Are Biosimilars the Future of Oncology and Haematology?

Authors:  Pier Luigi Zinzani; Martin Dreyling; William Gradishar; Marc Andre; Francisco J Esteva; Suliman Boulos; Eva González Barca; Giuseppe Curigliano
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

2.  Biosimilars as a strategy to improve sustainability.

Authors:  Emilio Bria; Pierfranco Conte
Journal:  ESMO Open       Date:  2017-05-29

Review 3.  The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond.

Authors:  Lin-Chau Chang
Journal:  J Food Drug Anal       Date:  2019-04-30       Impact factor: 6.157
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.